Question 1

What are the most cited papers from German Inflammatory Bowel Diseases Study Group?

Accepted Answer

The most cited paper from German Inflammatory Bowel Diseases Study Group is "Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia" (Hermann Schulz, 2002), with 206 citations. Next come "Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma" (175) and "Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma" (159).

Question 2

Which research topics does German Inflammatory Bowel Diseases Study Group publish most on?

Accepted Answer

By volume in 2022-now: Lymphoma Diagnosis and Treatment, Cultural Heritage Management and Preservation, Lung Cancer Treatments and Mutations and Cancer Immunotherapy and Biomarkers.

Question 3

Which keywords describe research at German Inflammatory Bowel Diseases Study Group?

Accepted Answer

By fractional works in all years, weighted toward what it does more of than the world: Rituximab, PET Imaging, Lymphoma, Classification, Molecular Profiling, Prognostic Factors, Targeted Therapy and Chemotherapy.

Question 4

Which fields of science does German Inflammatory Bowel Diseases Study Group work in?

Accepted Answer

In all years, 84% of research at German Inflammatory Bowel Diseases Study Group is in Health Sciences, 8% in Social Sciences. Its largest fields are Medicine (82%), Biochemistry, Genetics and Molecular Biology (4%), Immunology and Microbiology (3%). It does 3.1× the world's share of Health Sciences.

Question 5

Is German Inflammatory Bowel Diseases Study Group's research output growing?

Accepted Answer

Output in 2022-2025 was 22% lower than in 2018-2021.